Therapy-related B-lymphoblastic leukemia (B-ALL) following treatment for multiple myeloma is a rare occurrence.

A growing number of physicians are starting to shift their thinking about multiple myeloma’s prognosis. For years, patients ...

Halozyme Therapeutics (NASDAQ:HALO) announced on Wednesday that the European Commission has approved an injectable combo ...

Our real-world findings indicate that most patients undergoing multiple lines of therapy experience persistent treatment refractoriness and low response rates,” the researchers wrote.

Hematologist-oncologist Mateo Mejia Saldarriaga, MD, combines clinical care with research aimed at helping patients with ...

Therapy-related B-lymphoblastic leukemia (B-ALL) following treatment for multiple myeloma is a rare occurrence. Despite its rarity and the lack of recognition by the World Health Organization as a ...

A large U.S. registry study of ide-cel CAR-T therapy in relapsed/refractory multiple myeloma shows strong response rates and a safety profile comparable to clinical trials—even among older and ...

CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, ...

Researchers proposed changing the recommendations for universal driving restrictions after CAR T-cell infusion.

Marc Raab, MD, PhD, discussed the MajesTEC-5 trial of teclistamab plus standard myeloma therapies in transplant-eligible newly diagnosed multiple myeloma.

Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment ...

During a live event, Patrick Moore, MD, discussed the KarMMa-3 subgroup analyses and quality of life for patients with ...